HORAMINE

Description
Horamine Tablet: Round, yellow uncoated tablet, shallow convex faces; "HD" embossed and scored on the same face.
Horamine Syrup: Red, raspberry flavoured viscous liquid.

Composition
Horamine Tablet: Each tablet contains Chlorpheniramine Maleate 4 mg.
Horamine Syrup: Each 5 ml contains Chlorpheniramine Maleate 4 mg.

Pharmacodynamics
Chlorpheniramine acts by competing with histamine for H1-receptor sites on effector cells, thus preventing responses mediated by histamine. Its antimuscarinic actions will provide a drying effect on the nasal mucosa.

Pharmacokinetics
Chlorpheniramine is readily absorbed after oral administration, metabolised in the liver and excreted mainly in the urine. It is widely distributes throughout the body tissues and appears to be subjected to enterohepatic circulation. It is metabolized in the liver to form polar and non-polar metabolites.

Indications
For symptomatic treatment of:
Allergic or vasomotor rhinitis, hay fever, urticaria, angioneurotic oedema, sensitivity reactions and other itching skin conditions including pruritus ani, pruritus vulvae, pruritus of drug rashes, contact dermatitis and insect bites.

Contraindications
- Avoid in patients known to be hypersensitive to antihistamines.
- Use is not recommended in nursing mothers and in children below 6 years of age.

Warning and Precautions
This medication may cause drowsiness in some patients.
Caution when driving or operating machinery.
Avoid alcoholic beverages.

When used for treatment of cough and cold;
(a) Not to be used in children less than 2 years of age
(b) To be used with caution and doctor's / pharmacist's advice in children 2 to 6 years of age.

Pregnancy and Lactation
Pregnancy: The risk-benefit must be considered, although no association between any fetal abnormalities has been formed with chlorpheniramine.
Lactation: Small amount of chlorpheniramine are excreted in breast milk. Due to the higher risk of adverse effects of antihistamines in infants, the use of chlorpheniramine is not recommended in nursing mothers.

Drug Interactions
- Co-administration of alcohol, other CNS depressants, tricyclic antidepressants or atropine may potentiatethe effects of either these medications or chlorpheniramine.
- Concurrent use with monoamine oxidase (MAO) inhibitors may prolong and intensify the antimuscariniceffects of chlorpheniramine.

Main Side/ Adverse Effects
Drowsiness; dryness of mouth, nose, and throat; gastrointestinal disturbances.

Effects on ability to drive and use machines
This medication may cause drowsiness in some patients. Caution when driving or operating machinery. Avoid alcoholic beverages.

Overdose
Clinical features: Drowsiness, staggering gait, hallucinations, convulsions, respiratory depression, coma.
Treatment: Treat overdose by giving activated charcoal to delay absorption of ingested drug and then remove by airway- protected gastric lavage followed by catharsis. Control convulsions, if any, by giving IV 0.1 mg/kg diazepam.

Dosage and Administration
Adults Oral, 4 mg every four to six hours as needed, not exceeding 24 mg daily.
Children 6 to 12 years: Oral, 2 mg three or four times daily as needed, not exceeding 12 mg a day.
Note: The information given here is limited.
For further information, consult your doctor or pharmacist.

Storage : Horamine Tablet: Store below 30˚C. Protect from moisture.
Horamine Syrup: Store below 25°C. Protect from light.

Presentation/ packing : Horamine Tablet: Blister pack of 100's, Bottle pack of 100's, 1000's
Horamine Syrup: Syrup 4mg/5ml x 3.6L, 120ml, 100ml, 60ml
(Not all presentation are available locally)

Product Registration Holder : Hovid Bhd., 121, Jalan Tunku Abdul Rahman (Jalan Kuala Kangsar), 30010 Ipoh, Perak, Malaysia
Manufactured by : Hovid Bhd., Lot 56442, 7 ½ Miles, Jalan Ipoh / Chemor, 31200 Chemor, Perak, Malaysia.
Revision date : Sept 2018